- Home
- CLPS vs MBRX Comparison
CLPS vs MBRX Comparison
Compare CLPS & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPS | MBRX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 23.5M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CLPS | MBRX |
|---|---|---|
| Price | $0.85 | $4.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 19.4K | ★ 309.8K |
| Earning Date | 10-17-2025 | 11-13-2025 |
| Dividend Yield | ★ 15.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $164,481,414.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.17 | N/A |
| 52 Week Low | $0.82 | $4.36 |
| 52 Week High | $1.88 | $91.25 |
Technical Indicators
Market Signals| Indicator | CLPS | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 54.33 |
| Support Level | $0.84 | $4.75 |
| Resistance Level | $0.90 | $7.98 |
| Average True Range (ATR) | 0.03 | 0.71 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 4.44 | 50.85 |
Price Performance
Historical ComparisonAbout CLPS CLPS Incorporation
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.